NanoFlu, a recombinant quadrivalent influenza vaccine candidate that has been granted fast track status by the FDA , met all primary endpoints in a phase 3 trial testing its efficacy and overall safety in older adults, Novavax announced. The trial compared NanoFlu with Fluzone Quadrivalent (Sanofi Pasteur) using the […]
